Get started
Author

Amparo Yovanna Castro Sanchez

Observed names: A.Y. Castro Sanchez, Amparo Sanchez, Amparo Y. Castro Sanchez
Institution: Roche (Switzerland)
ORCID: 0000-0003-1174-0779
Observed ORCID: 0000-0003-1174-0779
OpenAlex ID: A5011698770
Glutathione and mitochondria determine acute defense responses and adaptive processes in cadmium-induced oxidative stress and toxicity of the kidney
2014 · Ambily Ravindran Nair, Wing-Kee Lee, et al. · Archives of Toxicology · 116
A mathematical model for HIV and hepatitis C co-infection and its assessment from a statistical perspective
2013 · Amparo Yovanna Castro Sanchez, Marc Aerts, et al. · Epidemics · 31
PDF
Brief Report: Updated Data From IMscin001 Part 2, a Randomized Phase III Study of Subcutaneous Versus Intravenous Atezolizumab in Patients With Locally Advanced or Metastatic NSCLC
2024 · Mauricio Burotto, Zanete Zvirbule, et al. · Journal of Thoracic Oncology · 16
Systematic literature review of methodologies and data sources of existing economic models across the full spectrum of Alzheimer’s disease and dementia from apparently healthy through disease progression to end of life care: a systematic review protocol.
2018 · Maria Karagiannidou, Raphael Wittenberg, et al. · BMJ Open · 13
PDF
Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer’s disease scale: development and results from a mapping study
2020 · Ines Rombach, Marvi Iftikhar, et al. · Quality of Life Research · 11
PDF
Assessing the impact of digital patient monitoring on health outcomes and healthcare resource usage in addition to the feasibility of its combination with at-home treatment, in participants receiving systemic anticancer treatment in clinical practice: protocol for an interventional, open-label, multicountry platform study (ORIGAMA)
2023 · Sanna Iivanainen, Anne-Marie Baird, et al. · BMJ Open · 8
PDF
244MO Primary results from IMscin002: A study to evaluate patient (pt)- and healthcare professional (HCP)-reported preferences for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC
2024 · F. Cappuzzo, Z. Zvirbule, et al. · ESMO Open · 7
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC
2025 · Federico Cappuzzo, Zanete Zvirbule, et al. · JTO Clinical and Research Reports · 6
PDF
Health‐Related Quality of Life, Physical Activity and Joint Health in People With Severe Haemophilia A Receiving Emicizumab: Results From the Phase IV HemiNorth 2 Study
2025 · Jan Astermark, Susanna Ranta, et al. · Haemophilia · 3
PDF
Systematic review of health economic models for assessment and diagnosis of dementia
2025 · Joseph Kwon, Lisanne Schoutens, et al. · Alzheimer s & Dementia Behavior & Socioeconomics of Aging · 2
PDF
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer
2025 · Margarita Majem, Busyamas Chewaskulyong, et al. · Oncology and Therapy · 1
PDF
Erratum to ‘Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC’ [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100815]
2025 · Federico Cappuzzo, Zanete Zvirbule, et al. · JTO Clinical and Research Reports · 1
Cough, dyspnea, or chest pain? an examination of the composite endpoint in metastatic non-small cell lung cancer clinical trials
2026 · Carla Mamolo, Tracy Holt, et al. · Quality of Life Research
MA10.06 IMscin002 Final Analysis: Patient Preference and Safety of Atezolizumab by Subcutaneous and Intravenous Administration
2025 · F. Cappuzzo, Z. Zvirbule, et al. · Journal of Thoracic Oncology
1854P IMscin001 final analysis: A randomised phase III study of subcutaneous (SC) versus intravenous (IV) atezolizumab (atezo) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
2025 · M. Burotto, Z. Zvirbule, et al. · Annals of Oncology
The impact of digital patient monitoring on health outcomes and healthcare resource utilization in patients receiving immunotherapy in clinical practice: Results from an early terminated study.
2025 · Sanna Iivanainen, Maria Reig, et al. · Journal of Clinical Oncology
62P Patient satisfaction and preference for atezolizumab subcutaneous (atezo SC) by body mass index (BMI) or race (Asian vs non-Asian) from IMscin001 and IMscin002
2024 · B. Chewaskulyong, Z. Zvirbule, et al. · Annals of Oncology
143P Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: Exploratory analyses from the IMscin002 study
2024 · M. Majem Tarruella, Z. Zvirbule, et al. · Immuno-Oncology Technology
1447P IMscin001 part 2 updated results: Efficacy, safety, immunogenicity and patient-reported outcomes (PROs) from the randomised phase III study of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
2023 · M. Burotto, Z. Zvirbule, et al. · Annals of Oncology
PDF
Works count: 19
Citation count: 215
H-index: 7
I10-index: 5
Year
Topic
Type